Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 265

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 8
Chunk 265
---
 the United States which the Secretary of Treasury of the United States determines is satisfactory for
purposes of this provision and which includes an exchange of information program, or (ii) with respect to any dividend it pays on stock
which is readily tradable on an established securities market in the United States. Any dividend paid by us in a taxable year in which
we are a PFIC (or with respect to which we were a PFIC in the preceding taxable year) will be subject to tax at regular ordinary income
rates. As mentioned above, we believe we may have been a PFIC for our 2024 taxable year and have not determined whether we will be a PFIC
for our 2025 taxable year. U. S. Investors should consult their own tax advisors regarding the availability of the lower rate for
dividends paid with respect to our ordinary shares and ADSs.

The additional 3.8% Medicare tax (described below) may apply to
dividends received by certain U. S. Investors who meet certain modified adjusted gross income thresholds.

Sale, Exchange or Other Disposition
of Ordinary Shares and ADSs. Subject to the discussion under “ - Passive Foreign Investment Company” below, a
U. S. Investor generally will recognize capital gain or loss upon the sale, exchange or other taxable disposition of ordinary shares or
ADSs in an amount equal to the difference between the amount realized on the sale, exchange or other taxable disposition and the U. S.
Investor’s adjusted tax basis in such ordinary shares or ADSs. This capital gain or loss will be long-term capital gain or loss
if the U. S. Investor’s holding period in the ordinary shares or ADSs exceeds one year. Preferential tax rates for long-term capital
gain will apply to individual U. S. Investors. The deductibility of capital losses is subject to limitations. The gain or loss will generally
be income or loss from sources within the United States for U. S. foreign tax credit purposes, subject to certain possible exceptions under
the Treaty. The additional 3.8% Medicare tax (described below) may apply to gains recognized upon the sale, exchange, or other taxable
disposition of our ordinary shares or ADSs by certain U. S. Investors who meet certain modified adjusted gross income thresholds.

U. S. Investors should consult their own tax advisors regarding
the U. S. federal income tax consequences of receiving currency other than Dollars upon the disposition of ordinary shares or ADSs.